Plant‐made pharmaceuticals: from ‘Edible Vaccines’ to Ebola therapeutics

As I sat writing this ‘personal reflections’ manuscript in the spring of 2015, I was seeing press reports related to the use of tobacco to make an Ebola therapeutic called ZMapp. For several months newspaper articles, radio shows and hour‐long TV documentaries have given the public unprecedented exposure to the fact that ‘plant‐made pharmaceuticals’ (PMP) can be life‐saving drugs. I have been asked by many nonspecialists – why tobacco? How can this work? After spending over twenty years doing research in this field and many, many hours in public policy meetings promoting PMPs as an important tool of public health, I do not tire of hearing the same questions. Although there is an increasing pipeline of new protein drugs that will come from plants for both human and animal health, the general public has little knowledge of these specialized tools and therefore limited support for the field. ZMapp has given us free advertising on an international scale that I could never have anticipated.

[1]  K. Steinback,et al.  Identification of the triazine receptor protein as a chloroplast gene product. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. G. Douglas.  The Children's Vaccine Initiative--will it work? , 1993, The Journal of infectious diseases.

[3]  M. Shuler,et al.  Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies. , 2003, Vaccine.

[4]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[5]  J. Dye,et al.  A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge , 2011, Proceedings of the National Academy of Sciences.

[6]  S. Marillonnet,et al.  Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Bohorova,et al.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant , 2011, Proceedings of the National Academy of Sciences.

[8]  S. Plotkin,et al.  Plant-derived vaccines and antibodies: potential and limitations. , 2005, Vaccine.

[9]  M. Herbst-Kralovetz,et al.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. , 2011, Vaccine.

[10]  D. M. Lam,et al.  Expression of hepatitis B surface antigen in transgenic plants. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Staehelin,et al.  Regulation of chloroplast membrane function: protein phosphorylation changes the spatial organization of membrane components , 1983, The Journal of cell biology.